OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
ROCKVILLE, Md., Feb. 23, 2017 -- Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that it will host its fourth quarter and full year 2016 financial results teleconference and webcast at 8:30 a.m. Eastern on Wednesday, March 8th. The press release announcing the financial results and operating highlights is expected to be released before the opening of capital markets that day.
Individuals interested in accessing the live audio webcast of the teleconference may do so at http://www.sucampo.com/investors/events-presentations/ and should log on 10 to 15 minutes before the teleconference begins to download any software required. Presentation slides will be available via the webcast link. A replay of the webcast will also be available on Sucampo’s website for several days after the live event. Alternatively, individuals may dial 888-636-8238 (domestic) or 484-747-6635 (international) and use passcode 71158094. A replay of the teleconference will be available by dialing 855-859-2056 (domestic) or 404-537-3406 (international), passcode 71158094, approximately two hours after the teleconference concludes. The archive of the teleconference will be available for 30 days.
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a pipeline of product candidates in clinical development. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan, Switzerland and the U.K. For more information, please visit www.sucampo.com.
The Sucampo logo and the tagline, The Science of Innovation, are registered trademarks of Sucampo AG. AMITIZA is a registered trademark of Sucampo AG.
Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn (Sucampo Pharmaceuticals).
Twitter LinkedIn
Contact: Sucampo Pharmaceuticals, Inc. Silvia Taylor Senior Vice President, Investor Relations and Corporate Affairs 1-240-223-3718 [email protected]
